KMG Fiduciary Partners LLC Has $2.49 Million Stock Position in Novo Nordisk A/S $NVO

KMG Fiduciary Partners LLC lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 30.5% in the second quarter, HoldingsChannel reports. The fund owned 51,957 shares of the company’s stock after selling 22,776 shares during the period. KMG Fiduciary Partners LLC’s holdings in Novo Nordisk A/S were worth $2,491,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the business. Loomis Sayles & Co. L P raised its stake in Novo Nordisk A/S by 6.0% in the 4th quarter. Loomis Sayles & Co. L P now owns 17,135,384 shares of the company’s stock worth $871,848,000 after purchasing an additional 969,916 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Novo Nordisk A/S by 5.1% during the 4th quarter. Franklin Resources Inc. now owns 14,702,508 shares of the company’s stock worth $748,064,000 after purchasing an additional 717,719 shares in the last quarter. Morgan Stanley grew its position in shares of Novo Nordisk A/S by 3.5% during the 4th quarter. Morgan Stanley now owns 12,842,089 shares of the company’s stock worth $653,406,000 after purchasing an additional 428,660 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Novo Nordisk A/S by 99.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after purchasing an additional 4,836,285 shares during the period. Finally, Arrowstreet Capital Limited Partnership acquired a new stake in shares of Novo Nordisk A/S in the first quarter valued at approximately $287,660,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Up 0.7%

Shares of NVO opened at $47.59 on Tuesday. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16. The company has a market cap of $212.49 billion, a P/E ratio of 11.64, a P/E/G ratio of 4.31 and a beta of 0.76. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm has a 50 day simple moving average of $47.07 and a two-hundred day simple moving average of $44.81.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The firm had revenue of $11.98 billion for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%. Research analysts forecast that Novo Nordisk A/S will post 3.39 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Tuesday, August 25th. Investors of record on Monday, August 17th will be given a dividend of $0.5786 per share. This represents a dividend yield of 254.0%. The ex-dividend date is Monday, August 17th. Novo Nordisk A/S’s dividend payout ratio is currently 42.79%.

Wall Street Analysts Forecast Growth

NVO has been the subject of several recent research reports. Weiss Ratings upgraded Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 5th. HSBC restated a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, July 20th. Wall Street Zen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, BMO Capital Markets reissued a “market perform” rating and set a $47.00 target price on shares of Novo Nordisk A/S in a report on Thursday. Five investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $65.81.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Analysts set a price target of $65.56 for Novo Nordisk, implying substantial potential upside from the stock’s recent trading level near $47.59. The target supports investor confidence despite recent concerns about the company’s growth outlook. Analysts Set Novo Nordisk A/S Price Target at $65.56
• Positive Sentiment: Novo Nordisk named Amazon Web Services its preferred global cloud and strategic artificial-intelligence partner. A new London innovation hub and AWS tools for drug targeting, therapy design, and clinical-data analysis could help shorten development timelines; more than 25,000 Novo employees have already used the partnership’s tools. Novo Nordisk and Amazon Web Services Collaborate to Advance Drug Discovery
• Positive Sentiment: Hims & Hers’ restructuring and move away from compounded GLP-1 medicines could reduce competition for Novo Nordisk’s approved branded obesity treatments. The development also highlights the regulatory and commercial advantages of established GLP-1 manufacturers. Hims Stock Falls on Earnings
• Neutral Sentiment: Novo Nordisk is supplying semaglutide for Veru’s fully enrolled Phase 2b PLATEAU trial. The combination study could broaden semaglutide’s future applications, but interim results are not expected until the first quarter of 2027. Veru Reports Fiscal 2026 Third Quarter Results and PLATEAU Trial Progress
• Negative Sentiment: Eli Lilly remains Novo Nordisk’s primary rival, with manufacturing capacity increasingly viewed as a competitive moat in the obesity-drug market. The comparison reinforces concerns that market share will depend not only on clinical results but also on each company’s ability to scale supply efficiently. Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.